The Traws Pharma, Inc. (NASDAQ: TRAW) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information on Traws’ clinical-stage antiviral programs, financial position, governance and executive compensation, and they complement the company’s press releases.
Through periodic reports such as the Form 10-K and proxy statements, Traws describes its business focus on developing investigational oral small molecule antivirals for respiratory viral diseases, including COVID-19, Long COVID, bird flu and seasonal influenza. The definitive proxy statement (DEF 14A) outlines board structure, incentive compensation plans and matters submitted to stockholders, while also providing context on corporate governance and director elections.
Current reports on Form 8-K, several of which are referenced in the provided data, document material events such as interim clinical data announcements for ratutrelvir, approval to proceed with Phase 2 COVID-19 studies, dosing of the first Phase 2 subjects, quarterly earnings releases, option and restricted stock unit grants to executives, and the appointment of new board members and officers. These filings also confirm that Traws’ common stock is listed on The Nasdaq Stock Market LLC under the symbol TRAW.
Investors and analysts can use this page to review how Traws reports on its clinical progress with ratutrelvir and tivoxavir marboxil, its legacy oncology programs rigosertib and narazaciclib, and its financial results and capital structure. Forms related to executive and director compensation, incentive plans and governance changes provide additional insight into how the company aligns management incentives with its development priorities.
Stock Titan enhances access to these filings by organizing them chronologically and by form type, and by offering AI-powered summaries that explain the key points of lengthy documents such as annual reports, quarterly updates and 8-Ks. This allows users to quickly understand the significance of new filings, track trends in Traws’ disclosures and identify items such as clinical milestones, financing arrangements or changes in leadership that may be important for evaluating TRAW stock.
Traws Pharma, Inc. (TRAW) reported a committed equity facility giving it the right, in its sole discretion, to sell an investor up to an aggregate of $50,000,000 USD of its common stock from time to time, subject to certain limitations. The notice lists $0 USD sold and $50,000,000 USD remaining to be sold.
Traws Pharma, Inc. (TRAW) registered for resale by Roth Principal Investments, LLC up to 135,135,135 shares of common stock that Traws may elect to issue and sell to Roth under a purchase agreement. After Commencement and satisfaction of the agreement’s conditions, Traws may sell up to $50,000,000 in aggregate gross proceeds, but is not obligated to sell shares. Traws receives no proceeds from Roth’s resales.
Purchases are generally priced at 94.0% of VWAP, a 6.0% discount; block purchases require Roth’s prior written consent and are priced at 94.0% of the closing price. Issuances are subject to a 3,072,118-share Exchange Cap, unless stockholders approve more shares or the average purchase price meets the $0.3663 Base Price and continues to do so, and to a 4.99% beneficial ownership limit. The registered share count is approximately 879.3% of the 15,368,277 shares outstanding as of October 22, 2026. Actual sales depend on Traws’ decisions and the agreement’s conditions.
Traws Pharma, Inc. entered into a Common Stock Purchase Agreement and a related Registration Rights Agreement with Roth Principal Investments, LLC, under which Traws may sell newly issued common stock for up to $50,000,000 in aggregate gross purchase price. Sales and their timing are solely at Traws’ discretion, and Traws is not required to sell shares.
The purchase period begins after the conditions are initially satisfied, including SEC effectiveness of a registration statement for Roth’s resale of shares, and ends on the first day of the month following the 36-month anniversary of Commencement unless terminated earlier. Purchases require a closing sale price of at least $0.10 on the prior trading day, or on the Purchase Date for post-market and block purchases. Issuance is capped at 3,072,118 shares, equal to 19.99% of shares outstanding immediately before the agreement, unless stockholder approval or an average purchase price at least equal to the $0.3663 Base Price applies. Roth and its affiliates also may not beneficially own more than 4.99% of outstanding shares. Any net proceeds depend on sales and prices, and Traws plans to use them for product-candidate development, working capital and general corporate purposes.
Traws Pharma, Inc. asks stockholders at its December 3, 2026 special meeting to authorize a 1-for-8 to 1-for-15 reverse split of common stock. If approved, the board could set the ratio and implement the split within 12 months after approval, without another stockholder vote, or abandon it. The company identifies Nasdaq’s $1.00 minimum bid-price requirement as one main reason for the proposal.
Traws Pharma received a Nasdaq deficiency notice after its closing bid price was below $1.00 for at least 30 consecutive business days and has until January 25, 2027 to regain compliance. The company says its stock could be delisted if stockholders reject the proposal and that a split would not assure continued listing. Authorized common shares would remain at 250,000,000; future issuance of authorized shares could dilute existing holders. The board recommends voting for both proposals, including adjournment to solicit additional proxies if needed.
Traws Pharma, Inc. (TRAW) asks stockholders to give its board discretionary authority to reverse-split common stock at a ratio from 1-for-8 to 1-for-15. If approved, the board may choose the ratio and act within 12 months after approval, without another stockholder vote; it may also abandon the split. A second proposal would allow adjournment to seek additional votes. The board recommends “For” both proposals.
The proposal addresses Nasdaq’s $1.00 minimum bid price requirement. Traws says Nasdaq notified it on July 29, 2026, after its closing bid price had been below $1.00 for at least 30 consecutive business days, and gave it until January 25, 2027, to regain compliance. Traws says its stock could be delisted if Proposal 1 is not approved; a closing bid of $0.10 or less for 10 consecutive trading days would trigger a Nasdaq delisting notice.
If implemented, outstanding common shares would be combined while 250,000,000 authorized common shares remain unchanged; options, warrants and plan reserves would be adjusted proportionately. Fractional shares would be rounded up, with no cash in lieu. The company says the split would increase authorized shares available relative to outstanding shares; future issuance could dilute holders. It also notes that fewer outstanding shares could impair liquidity and that continued Nasdaq listing is not assured.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of Traws Pharma, Inc. common stock. They disclose beneficial ownership of 1,555,423 shares of common stock, representing 9.5% of the class, held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.
The position includes 1,077,281 shares issuable upon exercise of warrants that are exercisable within 60 days, subject to a 9.99% beneficial ownership limitation. The 9.5% ownership figure is based on 16,445,558 shares outstanding, which includes the warrant shares and 15,368,277 shares outstanding as of August 12, 2026. The reporting persons emphasize that their filing does not constitute an admission of beneficial ownership or group status under the Exchange Act.
Traws Pharma, Inc. reported no revenue for the three and six months ended June 30, 2026, down from $2.7 million and $2.8 million in the prior-year periods after termination of a Symbio license. The company recorded a six‑month net loss of $10.2 million versus prior‑year net income driven by a large 2025 warrant revaluation gain. Cash and cash equivalents were $5.0 million with total assets of $11.5 million and an accumulated deficit of $650.1 million.
Research and development expenses rose to $6.0 million for the first half of 2026, reflecting higher virology spending on tivoxavir marboxil and ratutrelvir, while general and administrative costs increased to $5.5 million, largely from higher professional fees and stock‑based compensation. A $1.4 million legacy R&D accrual reversal reduced operating expenses. Management states that current cash will not fund operations for 12 months, and explicitly notes substantial doubt about the ability to continue as a going concern.
Liquidity was supported by an April 2026 private placement providing $10.0 million in gross proceeds (about $9.4 million net) and ATM sales adding $2.0 million. New April 2026 warrants could provide up to $50.0 million in additional gross proceeds if fully exercised for cash. Clinically, ratutrelvir showed favorable Phase 2 COVID‑19 results, but tivoxavir marboxil faces an MHRA deferral for a human challenge study and a U.S. FDA clinical hold. Traws also received a Nasdaq notice for failing the $1.00 minimum bid price requirement.
Traws Pharma, Inc. reported Q2 2026 results, highlighting continued investment in its antiviral pipeline and a more constrained balance sheet. For the quarter ended June 30, 2026, the company generated no revenue versus $2.7 million a year earlier, reflecting the absence of prior-period deferred revenue tied to a terminated oncology license. It reported a net loss of $3.1 million, or $0.16 per basic and diluted share, compared with a $0.9 million loss, or $0.11 per share, in Q2 2025.
For the first half of 2026, Traws recorded a net loss of $10.2 million, versus net income of $20.6 million in the first half of 2025, when results included a $26.7 million non-cash gain from changes in warrant liabilities. As of June 30, 2026, cash and cash equivalents were $5.0 million, up from $3.8 million at year-end, and total stockholders’ equity was $1.7 million versus a deficit of $0.6 million at December 31, 2025. Management expects existing cash plus anticipated at-the-market equity proceeds to fund operations into the first quarter of 2027, but indicates additional financing may be required thereafter.
Operationally, the company is advancing tivoxavir marboxil (TXM), an oral prophylactic candidate for seasonal and pandemic influenza, and working to address regulatory feedback. It plans to resubmit an updated toxicology package to the UK MHRA by the end of Q3 2026 to enable a Phase 2a human influenza challenge study at hVIVO, while also preparing a comprehensive response to resolve the FDA clinical hold on the US IND with a goal of advancing the program in the United States by the end of 2026. In April 2026, Traws closed a financing providing $10.0 million upfront and potential access to up to $50.0 million through milestone-based warrant tranches linked to MHRA approval and challenge-study data.
Traws Pharma, Inc. received an amended Schedule 13G filing (Amendment No. 4) from Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank. The group now reports beneficial ownership of 0 shares of Traws Pharma common stock, representing 0% of the class.
The filing states that each reporting person has no sole or shared voting power and no sole or shared dispositive power over any shares of Traws Pharma common stock, confirming that they collectively own 5 percent or less of the class.
Traws Pharma, Inc. received a disclosure that Sirenia Capital Management LP and Alex Silverstein are reporting beneficial ownership in its common stock through warrants. The Sirenia-managed funds hold Reported Warrants exercisable for 6,565,474 shares of common stock, based on 15,150,669 shares outstanding as of May 18, 2026. The warrants are subject to a 9.99% Blocker, which prevents exercises that would take the Reporting Persons above 9.9% of the outstanding common stock. As a result, they currently cannot exercise all of the Reported Warrants and their actual beneficial ownership is less than the full 6,565,474 shares issuable upon full exercise.